Table 1 Baseline patient characteristics
Characteristics | Experimental group No. (%) | Control group No. (%) | P |
|---|---|---|---|
Total No. of patient | 21 | 21 | Â |
Age(years) | |||
Median (range) | 52 (31–66) | 62 (48–65) | 0.024 |
Sex | Â | Â | 0.026 |
Female | 11 (52.4) | 4 (19.0) | Â |
Male | 10 (47.6) | 17 (81.0) | Â |
EMVI status | Â | Â | 0.500 |
Positive | 14 (66.7) | 15 (71.4) | Â |
Negative | 7 (33.3) | 6 (28.6) | Â |
MRF status | Â | Â | 1.000 |
Positive (cT3-cT4a) | 18 (85.7) | 18 (85.7) | Â |
Positive (cT4b) | 3 (14.3) | 3 (14.3) | Â |
Negative (cT3-cT4a) | 0 (0) | 0 (0) | Â |
Negative (cT4b) | 0 (0) | 0 (0) | Â |
MRI T stage | Â | Â | 0.371 |
cT3 | 18 (85.7) | 15 (71.4) | Â |
cT4a | 0 (0) | 3 (14.3) | Â |
cT4b | 3Â (14.3) | 3Â (14.3) | Â |
MRI N stage | Â | Â | 0.722 |
cN0 | 1 (4.8) | 3 (14.3) | Â |
cN1 | 6 (28.6) | 6 (28.6) | Â |
cN2 | 14 (66.7) | 12 (57.1) | Â |
Clinical stage | Â | Â | 0.226 |
II | 0 (0) | 3 (1.4) | Â |
IIIA | 0 (0) | 0 (1.4) | Â |
IIIB | 18 (85.7) | 13 (61.9) | Â |
IIIC | 3 (1.4) | 5 (23.8) | Â |
Tumor location | Â | Â | 1.000 |
Lower | 18 (85.7) | 19 (90.5) | Â |
Middle | 3 (14.3) | 2 (9.5) | Â |